Signal detection for vaccine side effects that have not been specified in advance

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 3, 2010, Pages 311-317

  Walker, Alexander M ^a,b  

^a WHISCON   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Adverse event; Information theory; Signal detection; Vaccine

Indexed keywords

ROTAVIRUS VACCINE; VACCINE;

ABDOMINAL PAIN; ADVERSE DRUG REACTION; ASTHMA; CHRONIC BRONCHITIS; DATA BASE; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG SURVEILLANCE PROGRAM; DYSPNEA; FATIGUE; FECES; FOOD AND DRUG ADMINISTRATION; GASTROENTERITIS; GASTROINTESTINAL HEMORRHAGE; HEMATURIA; HUMAN; INFORMATION SYSTEM; INTESTINE OBSTRUCTION; INTUSSUSCEPTION; MALAISE; NOTE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SIGNAL DETECTION; UNSPECIFIED SIDE EFFECT; URTICARIA; VACCINATION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATABASES, FACTUAL; HUMANS; INFLUENZA VACCINES; INFORMATION THEORY; TIME FACTORS; VACCINATION; VACCINES;

EID: 77649208526     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1889     Document Type: Note

References (27)

1. Walker AM, Jick H, Perera DR, Thompson RS, Knauss TA. Diphtheria! tetanus-pertussis immunization and sudden infant death syndrome. Am J Public Health 1987; 77: 945-952.
2. Walker AM, Jick H, Perera DR, Knauss TA, Thompson RS. Neurological events following diphtheria-tetanus-pertussis immunization. Pediatrics 1988; 8l: 345-349.
3. Liese JG, Meschievitz CK, Harzer E, et al. the Munich pertussis study group. Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr Infect Dis J 1997; 16: 1038-1044.
4. Kulldorff MDR, Kolczak M, Lewis E, Lieu T, Platt R. A maximized sequential probability ratio test for drug and vaccine safety surveillance, Working Paper. Available at http://www.dacp.org/faculty-Kulldorff.html.
5. Brown JS, Moore KM, Braun MM, et al. Active influenza vaccine safety surveillance: potential within a healthcare claims environment. Med Care 2009 [Epub ahead of print; DOI: 10.1097/MLR.0b013e318lb5865c].
6. Brown JS, KulldorffM, Chan KA, et al. Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiol Drug Saf 2007; 16: 1275-1284.
7. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast RG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071-1073.
8. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365: 475-481.
9. Velentgas P, West W, Cannuscio CC, Watson DJ, Walker AM. Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other nonaspirin non-steroidal anti-inflammatory medications. Pharmacoepidemiol Drug Saf 2006; 15: 641-652.
10. Walker AM, Wise RP. Precautions for proactive surveillance. Pharmacoepidemiol Drug Saf 2002; 11: 17-20.
11. Walker AM. Pattern recognition in health insurance claims databases. Pharmacoepidemiol Drug Saf 2001; 10: 393-397.
12. Lieu TA, Kulldorff M, Davis RL, et al. Real-time vaccine safety surveillance for the early detection of adverse events. Med Care 2007; 45 (10 Supl. 2): S89-95.
13. DuMouchelW. Bayesian data mining in large frequency tables, with an application to the FDA's spontaneous reporting system. Amer Statistician 1999; 53(3): 177-190.
14. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf 2002; 25(6): 381-392.
15. Niu MT, Erwin DE, Braun MM. Data mining in the US Vaccine Adverse Event Reporting System (VAERS): early detection of intussusception and other events after rotavirus vaccination. Vaccine 2001; 19: 4627-4634.
16. DuMouchel W, Smith ET, Beasley R, et al. Association of asthma therapy and Churg-Strauss syndrome: an analysis of postmarketing surveillance data. Clin Ther 2004; 26: 1092-1104.
17. Harrold LR, Patterson MK, Andrade SE, et al. Asthma drug use and the development of Churg-Strauss Syndrome (CSS). Pharmacoepidemiol Drug Saf 2007; 16(6): 620-626.
18. Law GR, Cox DR, Machonochie NE, Simpson J, Roman E, Carpenter LM. Large tables. Biostatistics 2001; 2(2): 163-171.
19. Cao H, Markatou M, Melton GB, Chiang MF, Hripcsak G. Mining a clinical data warehouse to discover disease-finding associations using co-occurrence statistics. AMIA Annual Symposium Proceedings 2005; 106-110.
20. Cao H, Hripcsak G, Markatou M. A statistical methodology for analyzing co-occurrence data from a large sample. J Biomed Informatics 2007; 40(3): 343-352.
21. Diaconis P, Efron B. Testing for independence in a two-way table. Ann Statist 1985; 13: 845-874.
22. Cao H, Melton GB, Markatou M, Hripcsak G. Use abstracted patient-specific features to assist an information-theoretic measurement to assess similarity between medical cases. J Biomed Informatics 2008; 41: 882-888.
23. Lin D. An information-theoretic definition of similarity. In Proceedings of the 15th International Conference on Machine Learning. Morgan Kaufmann, New York City: 1998; pp. 296-304 Available at http://ksuseer1.ist.psu.edu/viewdoc/summary; doi=10.1.1.55.1832
24. National Vaccine Injury Compensation Program. Vaccine Injury Table. http://www.hrsa.gov/vaccinecompensation/table.htm [Accessed 7 June 2009.]
25. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 28 May 2009. [Epub ahead of print; DOI: 10.1097/EDE.0b013e3181a663cc]
26. Pearson RK, Hauben M, Goldsmith DI, et al. Influence of the Med-DRA((R)) hierarchy on pharmacovigilance data mining results. Int J Med Inform 18 Feb 2009. [Epub ahead of print; DOI:10.1016/j.ijmedinf.2009.01. 001]
27. Walker AM. Looking back from the year2000. Drug regulation in the United States. J Clin Res Drug Devel 1989; 3: 259-264.